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Using CRISPR/Cas9-mediated gene 
editing to further explore growth 
and trade-off effects in myostatin-
mutated F4 medaka (Oryzias 
latipes)
Ying-Chun Yeh1, Masato Kinoshita2, Tze Hann Ng1, Yu-Hsuan Chang1, Shun Maekawa1, Yi-An 
Chiang1, Takashi Aoki1 & Han-Ching Wang1,3
Myostatin (MSTN) suppresses skeletal muscle development and growth in mammals, but its role in 
fish is less well understood. Here we used CRISPR/Cas9 to mutate the MSTN gene in medaka (Oryzias 
latipes) and evaluate subsequent growth performance. We produced mutant F0 fish that carried 
different frameshifts in the OlMSTN coding sequence and confirmed the heritability of the mutant 
genotypes to the F1 generation. Two F1 fish with the same heterozygous frame-shifted genomic 
mutations (a 22 bp insertion in one allele; a 32 bp insertion in the other) were then crossbred to produce 
subsequent generations (F2~F5). Body length and weight of the MSTN−/− F4 medaka were significantly 
higher than in the wild type fish, and muscle fiber density in the inner and outer compartments of the 
epaxial muscles was decreased, suggesting that MSTN null mutation induces muscle hypertrophy. From 
3~4 weeks post hatching (wph), the expression of three major myogenic related factors (MRFs), MyoD, 
Myf5 and Myogenin, was also significantly upregulated. Some medaka had a spinal deformity, and we 
also observed a trade-off between growth and immunity in MSTN−/− F4 medaka. Reproduction was 
unimpaired in the fast-growth phenotypes.
Myostatin (MSTN) is a member of the transforming growth factor-β (TGF-β) superfamily and is a well-known 
negative regulator of myogenesis in skeletal muscle development1–5. After MSTN is produced as a prepropeptide, 
a proteolytic process releases the C-terminal active domain of MSTN, which then dimerizes to become an acti-
vated peptide with biological activity6–9. The dimer of the MSTN C-terminal active domain subsequently interacts 
with membrane receptors and activates Smad2/3 signaling, which in turn initiates a signaling cascade that inhib-
its the expression of the myogenic regulatory factors (MRFs), including Myf5, myogenin and MyoD10–12. Double 
muscling (i.e. extreme gains in muscle mass) in MSTN-null phenotypes has been characterized in mammals13–15. 
This increase of muscle size in MSTN-null mammals may be caused by hypertrophy (increased muscle fiber size) 
or hyperplasia (increased number of muscle fibers) or both, and seems to be dependent on the animal species as 
well as the method used to suppress MSTN16, 17.
Fast-growing animals are usually preferred in commercial animal culture, and the effect of MSTN on fish first 
began to be studied nearly twenty years ago13. In fish, MSTN proteins are expressed ubiquitously in various tissues 
and organs, including those in the ingestion system and the reproductive system18–20. Most fish species carry two 
or more copies of MSTN. In teleosts, this has led to a diversification in MSTN functionality and/or mechanisms, 
and has given rise to various phenotypes in which changes in growth performance and skeletal muscle devel-
opment can occur via both hyperplasia and/or hypertrophy21–25. This diversity means that there is no universal 
fish research model for MSTN. In the present study, we chose to investigate MSTN function in medaka (Oryzias 
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latipes; rice fish). In evolutionary terms, medaka is separated from zebrafish by ~150 MY26. It is also unusual- and 
very convenient for our purposes- in that it has only a single copy of the MSTN gene27.
Methods that have previously been applied to generate MSTN-mutated medaka include transgenesis24, 
TILLING (targeting induced local lesions in the genome) by EMU-mutagenesis27, and TALENs (Transcription 
activator-like effector nucleases)22. Here, instead of temporary suppression by RNAi, or disabling MSTN by trans-
genesis or chemical mutagenesis, we used the CRISPR/Cas9 system to create several generations of MSTN−/− 
medaka. CRISPR/Cas9 has recently been developed into a powerful endonuclease-based gene editing tool that 
can be used to mutate specific genes in both eukaryotes and prokaryotes28–31, and we anticipated that it would 
provide several advantages over the currently available alternative platforms. In TALENs, for example, the design 
and construction of the specific DNA binding protein is more complicated, the overall process is more expensive, 
and the platform’s mutagenic efficiency is lower. Meanwhile, TILLING induces only an in-frame point mutation 
instead of frame shifts that cause the deletion of an entire functional domain. On the other hand, in the CRISPR/
Cas9 platform, the sgRNA can tolerate up to five mismatches, so it is necessary to ensure that no disruptive 
off-target effects are being induced at other genetic loci. In the first half of this study, after describing how we used 
the CRIPSR/Cas9 platform to produce MSTN−/− medaka, we confirm that all of the fish carried frame-shifted 
mutations and that there were no off-target effects. In the second half, we examine the growth performance of 
the knock-out fish in terms of body weight, body length and the development of muscle fibers. We also monitor 
the expression of MRFs (myogenic related factors). In addition, since there is often a trade-off between growth 
and other biological traits, such as immunity32 and reproduction33, we evaluate virus susceptibility by challenging 
the MSTN−/− medaka with RGNNV (red spotted grouper nervous necrosis virus) and assess their reproductive 
performance by monitoring both the number of eggs produced and the number of eggs that were successfully 
fertilized.
Results
Introduction of CRISPR/Cas9 mutations into the MSTN gene of medaka. The medaka genome 
contains only a single ortholog of the mammalian MSTN (OlMSTN; Ensembl gene no. ENSORLG00000015057), 
and we therefore designed our MSTN-sgRNA to specifically target this gene. As shown in Fig. 1, the active C 
terminal domain of MSTN is located in exon 3, and the MSTN-sgRNA target sequence was located upstream of 
this active domain on the 5′ end of the same exon.
Breeding the F2-F5 MSTN−/− medaka progeny and molecular characterization of their CRISPR/
Cas9-mediated mutations. Two F1 fish (F1#9 M and F1#34 F) with the same heterozygous mutation con-
sisting of a 22-bp insertion and a 32-bp insertion (Fig. 2A) were crossed with each other to generate the next gen-
eration of MSTN−/− medaka, F2. Two MSTN frame-shifted genotypes were found in 19 tested MSTN−/− medaka 
F2 progeny (Fig. 2A). One genotype was a homozygous frame-shift mutation with the same 22-bp insertion, 
while the other was a heterozygous mutation consisting of the 22-bp insertion and 32-bp insertion. Because the 
MSTN gene was successfully disrupted in all the tested MSTN−/− medaka F2 progeny, we were able to randomly 
select pairs of F2 mutants to produce the F3 generation of MSTN−/− medaka. Screening of the MSTN−/− F3 
medaka confirmed that all 6 of the tested fish carried the same two MSTN frame-shifted genotypes as the F2 fish 
(Fig. 2A). The F4 and F5 generations of MSTN−/− medaka were obtained in a similar way.
To confirm that there were no off-target effects, we used the web tool CHOPCHOP (https://chopchop.rc.fas.
harvard.edu/index.php) to predict possible off-targets for the MSTN sgRNA sequence used in this study. An 
off-target site was predicted at chr4:31195001 of the medaka genome (Suppl. Fig. S1A). We designed a PCR 
primer set to amplify this region, and performed PCR on genomic DNAs extracted from wild type (WT) and 
MSTN−/− medaka F5 medaka (Suppl. Fig. S1B). Sequencing showed that the resulting ~430 bp amplicons from 
WT and MSTN−/− F5 medaka were identical, suggesting that no off-target effect had occurred on chr4:31195001 
(Suppl. Fig. S1C).
Figure 2B further shows the predicted amino acid sequence of the mutated proteins, from which we infer 
that functional MSTN was no longer being expressed in either of these mutants. These results showed that our 
Figure 1. Our MSTN-sgRNA targets a location upstream of the active C-terminal domain of OlMSTN. (A) 
Schematic representation of the OlMSTN gene, which contains three exons, exon 1~3. The active C-terminal 
domain (black box) is found in exon 3. (B) The MSTN-sgRNA was designed to target a sequence (gray box) 
upstream of the active C-terminal domain in exon 3. The PAM sequence is shaded.
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MSTN-sgRNA CRISPR/Cas9 system successfully induced frame-shift mutations in exon 3 of the medaka MSTN 
genome, and that these genomic mutations were successfully transmitted to the subsequent generations. To check 
whether there was any frame-shift correction of the transcribed MSTN mRNA, we designed a PCR primer set to 
Figure 2. Genotypes of the two selected MSTN−/− medaka mutants produced by CRISPR/Cas9-mediated 
genome editing. (A) After sequence analysis confirmed that F1#9 M and F1#34 F both harbored the same two 
frame-shifted MSTN mutations, these two fish were used as a breeding pair. The offspring (F2) of F1#9 M x 
F1#34 F presented as one of two genotypes, both of which had CRISPR/Cas9-mediated frame-shifted MSTN 
mutation in both alleles. Randomly selected pairs were used to produce subsequent generations (F3-F5), all of 
which consisted entirely of the same two genotypes. The MSTN-sgRNA target sequence is underlined while the 
gray letters indicate the inserted nucleotides. (B) Corresponding amino acid sequences of exon 3 of the WT and 
two mutant genotypes. The targeted amino acids are shaded and the active C-terminal domain is boxed. The 
stop codon is represented by “−”.
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amplify the C-terminal region of the mRNAs from WT and MSTN−/− F5 medaka (Suppl. Fig. S2A). The expected 
22-bp insertion was detected in the C-terminus of the MSTN mRNA in each of the MSTN−/− F5 medaka (Suppl. 
Fig. S2B). However, in two of the knockout fish (MSTN−/− #5 and #8), an unexpected 61-bp deletion was some-
times detected even though the genotype of these MSTN−/− F5 medaka all showed the 22-bp insertion in the 
C-terminus of the MSTN gene. We therefore infer that the 61-bp deletion was probably due to an RNA splicing 
event during MSTN mRNA maturation. Fortunately, the 61-bp deletion still caused a frame-shifted mutation, 
suggesting that these fish would still have expressed MSTN with a non-functional C-terminus (Suppl. Fig. S2C). 
We therefore conclude that expression of the functional MSTN protein in the MSTN−/− F5 medaka was com-
pletely disrupted at least in all of the fish that we tested.
Growth performance and morphology of CRISPR/Cas9-mediated MSTN−/− F4 medaka. In 
general, MSTN mutations in both mammals and fish result in an increase in growth. We therefore investigated 
the growth performance of MSTN−/− F4 medaka from 1 to 8 wph (i.e. from juvenile to adult stages) by using two 
indicators, the standard length and body weight27. As shown in Fig. 3A,B, the growth performance of MSTN−/− 
F4 medaka was significantly better than that of WT. At 8 wph, compared with the WT group, relative body 
length and weight showed an increase of 10.0% and 64.9%, respectively. We also observed an accelerated increase 
in the body weight of the MSTN−/− F4 medaka at 6 and 8 wph compared to the corresponding WT controls 
(Fig. 3B). Although the MSTN−/− medaka exhibited a longer and wider body trunk than the WT controls, most 
of them showed relatively normal morphology (Fig. 3C). However, some of the mutants presented an observable 
deformity. Although the occurrence of this phenotype was not recorded in earlier generations, we observed severe 
spinal curvature in one of the MSTN−/− F4 medaka at 6 wph (Fig. 3C) as well as in several of the adult MSTN−/− 
F5 medaka (Suppl. Fig. S3A). To check the genotype of the three MSTN−/− F5 medaka in Suppl. Fig. S3A and 
two other MSTN−/− F5 medaka that also presented with the same spinal deformity, we used PCR followed by 
sequencing of the 450 bp amplicon that includes the MSTN-sgRNA target site. All of the tested deformed fish 
showed a homozygous 22 bp insertion at the target site (Suppl. Fig. S3B). (Unless otherwise noted, none of the 
deformed MSTN−/− medaka were used in subsequent parts of this study.)
The expression of MRFs in CRISPR/Cas9-mediated MSTN−/− F4 medaka. Because MSTN is 
known to activate the Smad2/3 pathway, which in turn leads to the down-regulation of MRFs (myogenic related 
factors), we next investigated the expression of the Smad2/3-regulated MRFs in MSTN−/− F4 medaka from 1 to 
8 wph. mRNA was extracted from whole WT and MSTN−/− F4 medaka and subjected to real-time PCR to detect 
the expression of three major MRFs: Myf5, Myogenin and MyoD22, 27. Starting from the post-juvenile stage (4 
wph) the expression levels of the three tested MRFs were significantly upregulated in the MSTN−/− F4 medaka 
(Fig. 4). Although these results do not demonstrate any direct relationship between MSTN knockout and Smad, 
they nevertheless suggest that within 4 weeks of hatching, the Smad 2/3 pathway may be suppressed in MSTN−/− 
F4 medaka.
Effect of CRISPR/Cas9-mediated MSTN mutation on skeletal muscle development in MSTN−/− 
F4 fish. To monitor skeletal muscle formation in MSTN−/− F4 fish, we tracked the muscle fiber cellularity and 
the muscle fiber area using histological analysis. For this experiment, we focused on the inner and outer compart-
ments of the epaxial muscles adjacent to the vertebral column as shown in Fig. 5A,B. Histological examination 
showed that the muscle fibers in both areas of the MSTN−/− F4 medaka at 6 wph had a larger cross-sectional 
area compared to those in WT medaka (Fig. 5C). This observation is reflected in the quantitative data shown in 
Fig. 5D,E. The cross-sectional area of the average muscle fiber in MSTN−/− F4 medaka at 6 wph was ~ 3 times 
bigger than that in WT medaka (Fig. 5D), while the muscle fiber cellularity of both the inner and outer compart-
ments of the epaxial muscles was significantly decreased in MSTN−/− F4 medaka at 6 wph (Fig. 5E). We further 
found that, even when there was a significantly different number of muscle fibers in these two compartments, the 
difference was relatively small (Fig. 5F). Taken together, these data suggest that CRISPR/Cas9-mediated MSTN 
mutation in MSTN−/− F4 fish caused muscle hypertrophy, not hyperplasia.
Effect of CRISPR/Cas9-mediated MSTN mutation on the response to virus challenge in 
MSTN−/− F4 fish. There is a well-known trade-off between growth and immunity that has been reported in 
a range of animals. To assess this effort in medaka, MSTN−/− F4 fish were challenged with RGNNV by immersion 
at 1 wph. RGNNV RNA2 expression was used as an indicator of the infection state (Fig. 6A), and the survival 
rate was also recorded (Fig. 6B). While the survival rates were almost identical in both groups, surprisingly, at 
2~3 days post immersion, the expression of RGNNV RNA2 was significantly lower in MSTN−/− fish. Although 
the reason for the low virus copy number is unknown, these results suggest that MSTN−/− fish are sensitive to 
RGNNV infection even when the copy number is low.
Effect of CRISPR/Cas9-mediated MSTN mutation on reproductive performance of MSTN−/− F4 
medaka. To assess reproductive performance of MSTN−/− F4 fish, we investigated the egg numbers and fer-
tilization rate of 3~4 pairs of WT and large phenotype/non-deformed MSTN−/− F4 medaka. During two months 
of observation, mean egg numbers were 9.1 and 9.7 in the samples of WT and MSTN−/− F4 medaka, while the 
fertilization rates were 83% and 86%, respectively (Fig. 7). There was no significant difference in these two repro-
ductive indicators between the WT and MSTN−/− F4 medaka. We conclude that CRISPR/Cas9-mediated MSTN 
mutation does not significantly affect the reproductive performance of MSTN−/− F4 medaka.
Discussion
Although the CRISPR/Cas9 system is now widely used to edit target genes in various mammals22, 23, 34–37 and in 
zebrafish, it is still only rarely applied to other fish species. Even in medaka, which is another fish model animal, to 
www.nature.com/scientificreports/
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date, there has only been one published study. This recent study was the first to use CRISPR/Cas9 to successfully 
target the medaka Dj-1 gene, and it also showed how the resultant mutation in the founder (F0) generation could 
subsequently be transmitted to the F1 genotypes38. Here in the present study, by using the CRISPR/Cas9 system, 
we not only document the mutated MSTN genotypes of the MSTN−/− medaka, we also continued to observe the 
Figure 3. CRISPR/Cas9-mediated MSTN−/− F4 medaka show better growth parameters. (A) Body weight and 
(B) standard length of wild type (WT) and MSTN−/− F4 medaka. Values represent the mean ± SD from seven 
individual samples. Asterisks indicate a significant difference (*p < 0.05, **p < 0.01 and ***p < 0.001) between 
WT and MSTN−/− F4 medaka. (C) Morphology of WT and MSTN−/− F4 medaka from 1–8 wph. At 6 weeks 
post-hatching (wph), one of the MSTN−/− fish had a spinal deformity (arrow head).
www.nature.com/scientificreports/
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specific phenotypes through to the F4 and F5 generations. Although other platforms have been used to generate 
MSTN-mutated fish, to our knowledge, this is the first investigation of the MSTN−/− phenotypes produced by 
the CRISPR/Cas9 system in medaka, and also the first to document the MSTN−/− fish for several generations.
Myostatin is a key suppressor of skeletal muscle growth that prevents overdevelopment via the activation of 
the Smad2/3 pathway to decrease the expression of MRFs, and as expected, in the MSTN−/− F4 medaka, three 
major MRFs were upregulated from 4 weeks post hatching (Fig. 4). Similar results were found for the same three 
MRFs (MyoD, Myf5 and Myogenin) in TALENs-mediated MSTN−/− F2 medaka22. Like most MSTN-deficient 
terrestrial vertebrates and fishes27, 39, CRISPR/Cas9-mediated MSTN−/− medaka also showed a phenotype with 
better growth performance (Fig. 3), with the acceleration of body weight being proportionally greater than the 
increase in body length. This body shape, ie the thicker body trunk, is consistent with the phenotypical changes 
that are seen in transgenic zebrafish that express MSTN antisense RNA21, MSTN C315Y mutant medaka pro-
duced by the TILLING method27 and TALENs-mediated MSTN−/− medaka22. Clearly, all of these results suggest 
that MSTN deficiency in medaka results in an increase of the growth rate. We further note that this is true even 
though all the medaka in the TALENs study, both WT and MSTN−/−, had a phenotype with a much longer body 
Figure 4. Gene expression levels of myogenic regulatory factors (MRFs) were increased in MSTN−/− F4 
medaka. Gene expression in each sample was analyzed by real-time PCR, and the expression levels of the 
MRFs were normalized against EF-1α mRNA levels. The relative expression levels are shown as fold change 
compared to the WT group. Each bar represents the mean ± SD from 6–7 individual samples. Asterisks indicate 
a significant difference (*p < 0.05, **p < 0.01 and ***p < 0.001) between WT and MSTN−/− medaka.
www.nature.com/scientificreports/
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than the fish used in the present study (eg ~17 mm and ~90 mg at 8 wph for WT in the TALENs study, versus ~10 
mm and ~95 mg at 8 wph in the present study).
Muscle mass depends on both the number and size of the muscle fibers, and myostatin appears to be able to 
act on both40. Thus when down-regulation or mutation of MSTN leads to an increased growth rate in most mam-
mals and various fish species, this can be due to either hypertrophy and/or hyperplasia. However, the observed 
effects are not always consistent even within a species, with different platforms sometimes producing opposite 
results. For example, mice with a MSTN C313Y missense mutation showed hyperplasia without hypertrophy16, 
while MSTN knockout mice in which the C-terminal region was replaced by a neo cassette had an increased mus-
cle mass that was due to both hypertrophy and hyperplasia1. This difference cannot simply be due to incomplete 
vs complete removal of MSTN functionality by the two respective platforms, because another study reported 
that transgenic mice that expressed a dominant negative MSTN also showed hypertrophy with hyperplasia41. 
Similarly inconsistent phenotypes have also been found in zebrafish. Zebrafish that expressed a dominant neg-
ative MSTN showed hyperplasia without hypertrophy23, whereas transgenic zebrafish that expressed MSTN 
antisense RNA as well as zebrafish in which MSTN had been transiently inactivated by oral administration of 
MSTN D76A dominant negative recombinant protein both presented with hypertrophy only21, 42. In the present 
study, our use of the CRISPR/Cas9 platform to disrupt the bioactive C-terminal domain in exon 3 of the medaka 
MSTN genes (Figs 1 and 2; Suppl. Fig. S2) would have completely prevented expression of the functional MSTN 
active domain. As noted above, histological analysis showed that while the mean diameter of the muscle fibers 
Figure 5. Histological sections showed evidence of hypertrophic muscle growth in MSTN−/− F4 fish. (A) The 
cross-sections used in this assay were taken from the area shown in the white box. (B) Typical cross-section 
showing location of the inner and outer compartments24 of the epaxial muscles adjacent to the vertebral 
column. (C) H&E staining of the muscle fibers in the indicated compartments of WT and MSTN−/− medaka 
at 2 and 6 wph. (D) Cross-sectional muscle fiber area in the inner and outer compartments (as measured in 
10 muscle fibers in 3~4 fish). (E) Muscle fiber density and (F) total numbers of fibers (as measured in 3~4 
fish). Values represent the mean ± SD. Asterisks indicate a significant difference (*p < 0.05, **p < 0.01 and 
***p < 0.001) between WT and MSTN−/− medaka.
www.nature.com/scientificreports/
8SCIeNTIfIC REPORTS | 7: 11435  | DOI:10.1038/s41598-017-09966-9
in MSTN−/− F4 fish was 2.7~2.9 fold larger than in WT (Fig. 5D,E), there was no increase in the number of 
muscle fibers (Fig. 5F). These results suggest that hypertrophy, not hyperplasia, is the prime mechanism of the 
additional muscle growth in CRISPR/Cas9-mediated MSTN−/− medaka. By contrast, in MSTN C315Y mutant 
medaka produced by the TILLING method, hypertrophy became significant only at the late adult stage (16 wph) 
while mstnC315Y-induced hyperplasia was seen from the post-juvenile stage onward27. Further, in 6-month-old 
transgenic medaka in which the dominant-negative form of myostatin was overexpressed, the cross-sectional area 
Figure 6. Evidence of increased virus susceptibility of MSTN−/− F4 fish. (A) Relative expression level of 
RGNNV RNA2. Since RGNNV is an RNA virus, the amount of RGNNV RNA2 reflects both the number of 
virus genome copies plus the transcribed virus mRNA. (B) The survival rate after immersion challenge with 
RGNNV. Values represent the mean ± SD. Asterisks indicate a significant difference (*p < 0.05, **p < 0.01 and 
***p < 0.001) between WT and MSTN−/− medaka.
Figure 7. Egg production and fertilization rate of MSTN−/− F4 medaka were not impaired. (A) The number of 
eggs and (B) fertilization rates were monitored in females of breeding pairs in WT and MSTN−/− F4 medaka 
at 20 sampling time points during 2 months. Values represent the mean ± SD from four pairs of WT and 
three pairs of large phenotype/non-deformed MSTN−/− F4 medaka. Asterisks indicate a significant difference 
(*p < 0.05, **p < 0.01 and ***p < 0.001) between WT and MSTN−/− medaka.
www.nature.com/scientificreports/
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of each muscle fiber was actually reduced while the number of fibers increased by a factor of between 1.8~2.4 24. 
It will probably not be easy to tease apart the extent to which these results are due to the different platforms. 
Nevertheless, it seems likely that the presence of endogenous full-length MSTN, even with a TILLING-induced 
in-frame point mutation, might well lead to different phenotypes than those seen in the off-frame mutations pro-
duced by CRISPR/Cas9. To explore these possibilities in detail, more work will need to be done.
Even though most of the CRISPR/Cas9-mediated MSTN−/− medaka had an acceptable, relatively normal 
body shape with a thicker body trunk, some of them (in one batch of 60 eggs, as many as 7 individuals [~12%]) 
had a spinal deformity (Figs 3C and S3A). This phenotype may have been due to disruption of bone formation, 
and curiously, we note that MSTN has previously been shown to regulate bone formation in mice: in MSTN 
knockout mice, total bone cross-sectional area, callus strength and bone mineral density were all increased43, 
and some tendons also become smaller and less flexible44. Nevertheless, at this time, the underlying reason for 
these spinal deformities is still unknown, and in particular the extent to which myostatin may have been involved 
remains unclear.
It is a fundamental concept that in the course of an organism’s life history, it needs to allocate resources between 
competing physiological processes and attempt to optimize the trade-off between various fitness-enhancing 
traits. One commonly observed trade-off in fish is growth versus reproduction45–47. However in the present study, 
we found that the reproductive ability of the large phenotype CRISPR/Cas9-mediated MSTN−/− medaka was 
not affected (Fig. 7). Another well-known example is the trade-off between growth and immunity. This kind of 
trade-off has been studied in poultry32, bull calves48 and sticklebacks49. In a previous study, we also found that 
TALENs-mediated MSTN−/− medaka had both a larger phenotype and a compromised immune system22. In 
those fish, there was a down-regulation of immune genes, significantly higher accumulation of virus, and an 
increased susceptibility to infection by RGNNV. By contrast, when we challenged the CRISPR/Cas9-mediated 
MSTN−/− medaka with the same virus, we found that the virus copy numbers were even lower than in WT 
(Fig. 6A). The reason for this discrepancy is not clear, but it may be related to the different phenotypes used in 
the two studies; as noted above, the fish used here were ~40% shorter than those in the TALENs study. Although 
it is difficult to directly compare results across these two studies, in the present case, by diverting more resources 
toward growth, the medaka might reduce the availability of these resources to the virus – and thus limit the 
virus’s ability to replicate. Nevertheless, despite the reduced viral load, the mortality rate of the MSTN−/− F4 
medaka was almost identical to that of the WT (Fig. 6B), suggesting that the immune system in these fish must 
somehow be impaired and that their susceptibility was greater. This further suggests that while both TALENs and 
CRISPR/Cas9 systems induce similar muscle growth in MSTN−/− fish, at the same time, they also compromise 
the immune system in different ways. If so, a side-by-side comparison of these two platforms might provide some 
very useful insights into the underlying mechanisms of immune suppression in MSTN−/− medaka.
Materials and Methods
Experimental fish and ethics statement. The medaka (Oryzias latipes; Cab strain) used in this study 
were maintained in transparent plastic rearing containers with a recirculating water system at 28 °C, and a 
14/10-h day/night cycle. The fish were fed three times a day with freshly hatched Artemia nauplii or commercial 
feed. All animal experiments in this study were approved by the Laboratory Animal Center of National Cheng 
Kung University and carried out in accordance with approved guidelines.
Vectors used for Cas9 nuclease and sgRNA expression. The two plasmids used for the CRISPR/
Cas9 system in this study were obtained from Addgene: pCS2 + hSpCas9 (#51815) and pDR274 (#42250). The 
pCS2 + hSpCas9 vector is the Cas9 expression vector with a SP6 promoter for Cas9 nuclease expression, while the 
pDR274 vector has a T7 promoter and was used for sgRNA expression.
sgRNA design and cloning into the expression vector. The genomic sequence of medaka mstn 
(OlMSTN) was obtained from the medaka genome database at the Ensembl Genome Database Project (Ensembl 
gene no. ENSORLG00000015057). Design and construction of OlMSTN-sgRNA followed a previously described 
protocol38, 50. In brief, the selected target site of the OlMSTN-sgRNA was a sequence of the form 5′- N21GG -3′, 
as recommended in a design guideline published by Ran et al.31. A pair of the selected OlMSTN-sgRNA oligo-
nucleotides in the sense and antisense directions were synthesized by Mission Biotech Co., Ltd. (Taiwan) using 
an oligonucleotide purification cartridge (OPC). The OlMSTN sgRNA was then cloned into the pDR274 vector 
using the protocols described in Ansai and Kinoshita38. The sequences of the OlMSTN-sgRNA oligonucleotides 
are listed in Table 1.
Synthesis of Cas9 mRNA and OlMSTN-sgRNA. After pCS2 + hSpCas9 was digested by NotI treatment, 
this linearized vector was used as the template for synthesizing capped Cas9 mRNA with a mMessage mMachine 
SP6 Kit (Life Technologies). The resulting Cas9 mRNA was purified by using a RNeasy Mini Kit (Qiagen). For 
synthesis of OlMSTN-sgRNA, the pDR274 vector containing OlMSTN-sgRNA was first digested by DraI and 
then used as the template for sgRNA synthesis using an AmpliScribe T7-Flash Transcription Kit (Epicentre). 
Ammonium acetate precipitation was used to purify the synthesized OlMSTN-sgRNA.
Embryo microinjection of Cas9 mRNA and OlMSTN-sgRNA. Microinjection of the medaka embryos 
followed a method described previously by Kinoshita et al.51. In brief, fertilized eggs were collected within 30 min 
after spawning and kept in pre-chilled Iwamatsu’s balanced salt solution52 at 4 °C to arrest development. A mix-
ture containing 100 ng/µL of Cas9 mRNA and 25 ng/µL of OlMSTN-sgRNA was prepared and injected into the 
fertilized eggs at the one-cell stage. The injected embryos were then incubated at room temperature in medaka 
embryo culture medium (0.0001% methylene blue, 0.1% NaCl, 0.3% KCl, 0.004% CaCl2. 2H2O, 0.016% MgSo4. 
7H2O). After hatching, the larvae were raised to sexual maturity and used as “founder” fish (F0).
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Detection of OlMSTN-CRISPR/Cas9 mediated DNA mutations in F0 founder fish and their 
offspring. To observe the genomic DNA mutations induced by Cas9 and OlMSTN-sgRNA in CRISPR/
Cas9-mediated MSTN-mutated medaka, a small piece of the caudal fin from individual F0 fish was collected 
and subjected to genomic DNA analysis as previously described22, 38. The primer set OlMSTN F2/OlMSTN 
R3 (Table 1) was used to amplify the region containing the OlMSTN-sgRNA target site in the genomic DNAs 
extracted from wild type (WT; non-genome-edited Cab strain) and CRISPR/Cas9 treated medaka. The resulting 
amplicons were then analyzed by heteroduplex mobility assay (HMA) as described previously53. The amplicons 
were also cloned into TA cloning vector (Bioman, Taiwan) and the mutations were sequenced. After the above 
screening had confirmed the occurrence of CRISPR/Cas9-mediated MSTN mutation in the F0 generation, these 
founder fish were crossed with each other, and their offspring (F1) were checked for MSTN mutations in the same 
way.
Breeding of the F2-F5 MSTN−/− generations. Two of the F1 MSTN−/− progeny with the same 
frame-shifted mutation patterns, F1#9(M) and F1#34(F), were mated to produce the F2 generation. The F2 gen-
eration were crossed with each other to produce F3 progeny, and the F4 and F5 progeny were subsequently bred 
in the same way. The F2 and F3 generations were screened as described above to confirm that the same mutation 
patterns were successfully inherited. Since F3 was the first generation to produce enough fish for the following 
assays, only F4 fish were used for this study.
Collection and assessment of WT and MSTN−/− F4 medaka. WT and F4 eggs were collected daily, 
and each cohort of larvae (~30) from eggs collected on the same day were maintained in a separate plastic rearing 
container (3 L) under a 14/10-h day/night cycle at 26 °C. For each group of WT and MSTN−/− F4 fish, at least 
7 tanks were used for growth assessment, quantification of the expression of MRFs (myogenic related factors) 
genes expression, and histological analysis. At 1, 2, 3, 4, 6 and 8 weeks post-hatching (wph), 7 individual fish were 
collected for growth assessment and quantification of gene expression. At 2 and 6 weeks post-hatching, another 
7 individual fish were collected and fixed for histological analysis using Davidson’s fixative solution (33% EtOH, 
22% formalin, and 11.5% acetic acid).
Growth assessment of WT and MSTN−/− F4 medaka. To determine the growth phenotype of WT 
and CRISPR/Cas9-mediated MSTN−/− F4 medaka, the body weight and standard length were measured using a 
protocol described previously22. Briefly, after fish were anesthetized in 0.003% eugenol (Sigma-Aldrich, Inc., MO, 
USA), the fish were weighed, and after being photographed under a digital microscope, their standard length was 
measured. The same fish were then immediately transferred to a 1.5 ml tube containing RNA keeper (Protech 
Technology Enterprise Co., LTD) and subjected to RNA extraction.
Quantification of the mRNA expression of myogenic related factors (MRFs) in WT and 
MSTN−/− F4 medaka using real-time PCR. For this experiment, 7 individual WT and MSTN−/− F4 
medaka were collected at 1, 2, 3, 4, 6 and 8 weeks post-hatching as described above. After RNA extraction, 
total cDNA was synthesized from each sample using Superscriptase II Reverse Transcriptase (Invitrogen) 
with Anchor-dTv primer (Table 1). To quantify the relative expression of three major MRFs (MyoD, Myf5 and 
Myogenin) and the normalization factor EF-1α, real-time PCR was performed with the specific primer sets listed 
in Table 1. Data values were calculated by the 2−ΔΔCT method and the expression level of each gene in the WT 
group was set to 1. Statistically significant differences between WT and MSTN−/− F4 medaka were analyzed by 
Student’s t-test.
Name Sequence (5′-3′) Usage Reference
MSTN-gRNA
OlMSTN-Sense* TAGGAAGATCTCAGAGGGCCCC CRISPR/Cas9 
target site This studyOlMSTN- Antisense* AAACGGGGCCCTCTGAGATCTT
Primers
OlMSTN_F2 TCAAGTGCTCACTCAGGCTG PCR for OlMSTN 
genotype ENSORLG00000015057OlMSTN_R3 CCACCGTGAGTGGGTAGC
OlMyoD-qPCR-F GCCCCCGCTCCAACTG
qPCR Chiang et al.22
OlMyoD-qPCR-R CGTCTGACACCTCGGTCCAT
OlMyf5-qPCR-F CGGCGGCTCAAAAAGGT
qPCR Chiang et al.22
OlMyf5-qPCR-R GAGGTGCAGCGCCTCAGT
OlMyogenin-qPCR-F TTGCCCACCATGGAGCTT
qPCR Chiang et al.22
OlMyogenin-qPCR-R AGCGCTGGTCAGGAAAGAAG
NNV_RNA2_qPCR_F 5′- GACGCGCTTCAAGCAACTC -3′
qPCR Chiang et al.22
NNV_RNA2_qPCR_R 5′- CGAACACTCCAGCGACACAGTA -3′
OlEF-1α-qPCR-F ATTTGCGGGGTTTGCAC
qPCR Chiang et al.22
OlEF-1α-qPCR-R TGGGACTTTTATACGGACTGG
Anchor-dTv GACCACGCGTATCGATGTCGACTTTTTTTTTTTTTTTTV cDNA synthesis
Table 1. MSTN-sgRNA and PCR primers used in this study. *Cutting sites are italicized.
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Histological analysis of skeletal muscle and muscle fiber density in WT and OlMSTN-CRISPR/
Cas9 mediated MSTN−/− F4 medaka. WT and MSTN−/− medaka were fixed with Davidson’s fixative 
solution and decalcified using EDTA solution (400 mM EDTA, 50 mM Tris-HCl, pH8.3) as described by Chisada 
et al.27. Before routine dehydration and paraffin embedding, the fixed fish were pre-embedded in agar-gelatin 
mixture (1% agar dissolved in 2.5% gelatin solution [300 Bloom])54. Paraffin sections (4 μm) were mounted 
on glass slides, dewaxed and dehydrated, and then stained with hematoxylin and eosin. Muscle formation was 
measured following the protocol described by Sawatari et al.24 and Chisada et al.27. Briefly, cross-sections of all 
specimens were made at the anterior end of the anal fin in the anteroposterior direction. In the inner and outer 
compartments of the epaxial muscles adjacent to the vertebral column, we used ImageJ software (http://rsb.info.
nih.gov/ij/) to count the total number of fibers, muscle fiber cellularity (i.e. density of muscle fibers), and the 
cross-sectional muscle fiber area in 3~5 fish from each group. Statistically significant differences between WT and 
MSTN−/− F4 medaka were analyzed by Student’s t-test.
The response to virus challenge in WT and OlMSTN-CRISPR/Cas9 mediated MSTN−/− F4 
medaka. Medaka at 1 week after hatching were challenged with RGNNV (red spotted grouper nervous 
necrosis virus) by bath immersion following the method described by Furusawa et al.55 and Chiang et al.22. 
Briefly, fish were challenged RGNNV at 109 TCID50 RGNNV/L for 2 h and then transferred to tanks containing 
ultraviolet-treated water and 5 μg/ml kanamycin. The survival rate was monitored daily in two groups of 15 fish 
each. Two more groups of ~20 fish were used to assess the virus load by monitoring the gene expression of the 
coat protein encoded by RGNNV RNA2 (AY44705). Total RNAs were extracted from three fish from these groups 
at 1, 2, 3 and 5 days post immersion (dpi). cDNA synthesis was performed by using Superscriptase II Reverse 
Transcriptase (Invitrogen) and Random hexamer primer. Real-time PCR was then used to measure the expres-
sion of RGNNV RNA2 with the primer set NNV_RNA2_qPCR_F/ NNV_RNA2_qPCR_R (Table 1). The expres-
sion of RGNNV RNA2 was normalized with EF-1α by the 2−ΔΔCT method and the expression level of RGNNV 
RNA2 at 0 dpi in the WT group was set to 1. Statistically significant differences between WT and MSTN−/− F4 
medaka were analyzed by Student’s t-test.
Reproductive performance of WT and OlMSTN-CRISPR/Cas9 mediated MSTN−/− F4 
medaka. To determine the reproductive performance of MSTN−/− F4 medaka, three pairs of WT and 
MSTN−/− F4 medaka were selected at random. Eggs from the female of each breeding pair were collected every 
2~3 days for 2 months to give a total of 20 samples. For each sample, we recorded both the number of eggs pro-
duced and the number of successfully fertilized eggs as observed under a light microscope. Statistically significant 
differences between WT and MSTN−/− F4 medaka were analyzed by Student’s t-test.
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